Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Unlabeled Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Metalyse; Belgium: Metalyse; Bulgaria: Metalyse; Cyprus: Metalyse; Czech Republic: Metalyse; Denmark: Metalyse; Estonia: Metalyse; Finland: Metalyse; France: Metalyse; Germany: Metalyse; Greece: Metalyse; Hungary: Metalyse; Ireland: Metalyse; Italy: Metalyse; Latvia: Metalyse; Lithuania: Metalyse; Luxembourg: Metalyse; Malta: Metalyse; Netherlands: Metalyse; Poland: Metalyse; Portugal: Metalyse; Romania: Metalyse; Slovakia: Metalyse; Slovenia: Metalyse; Spain: Metalyse; Sweden: Metalyse; UK: Metalyse.

North America

Canada: TNKase; USA: TNKase.

Latin America

Brazil: Metalyse; Mexico: Metalyse.

Drug combinations


Tenecteplase: C~2558~H~3872~N~738~O~781~S~40~. Mw: approx. 58742.01 (polypeptide portion only).103-L-Asparagine-117-L-glutamine-296-L-alanine-297-L-alanine-298-L-alanine-299-L-alanineplasminogen activator (human tissue type). CAS-191588-94-0 (1997).

Pharmacologic Category

Thrombolytic Agents. Enzymes. (ATC-Code: B01AD11).

Mechanism of action

Initiates fibrinolysis by binding to fibrin and converting plasminogen to plasmin.

Therapeutic use

Management of ST-elevation myocardial infarction for lysis of thrombi in coronary vasculature to restore perfusion and reduce mortality.

Pregnancy and lactiation implications

Administer to pregnant women only if potential benefits justify risk to fetus. Use with caution in pregnancy; increased risk of bleeding. Use with caution in lactation.

Unlabeled use

Acute MI-combination regimen of tenecteplase, abciximab, and heparin.


Hypersensitivity to tenecteplase or any component of the formulation. Active internal bleeding. History of stroke. Intracranial/intraspinal surgery or trauma within 2 months. Intracranial neoplasm. Arteriovenous malformation or aneurysm. Bleeding diathesis. Severe uncontrolled hypertension.

Warnings and precautions

Coronary thrombolysis may result in reperfusion arrhythmias. Cholesterol embolism rarely reported. For the following conditions risk of bleeding is higher with use of tenecteplase and should be weighed against benefits of therapy: recent (within 10 days) major surgery (e.g. CABG, obstetrical delivery, organ biopsy, previous puncture of noncompressible vessels), cerebrovascular disease, recent (within 10 days) GI or GU bleeding, recent trauma (within 10 days) including CPR, hypertension, high likelihood of left heart thrombus (e.g. mitral stenosis with atrial fibrillation), acute pericarditis, subacute bacterial endocarditis, hemostatic defects including those caused by severe renal or hepatic dysfunction, significant hepatic dysfunction, diabetic hemorrhagic retinopathy or other hemorrhagic ophthalmic conditions, septic thrombophlebitis or occluded AV cannula at seriously infected site, and/or any other condition in which bleeding constitutes a significant hazard or would be particularly difficult to manage due to location. Use with caution in patients receiving oral anticoagulants (increased risk of bleeding), and in recent administration of GP IIb/IIIa inhibitors. Concurrent heparin anticoagulation may contribute to bleeding. Avoid intramuscular injections. Caution with readministration of tenecteplase.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart